FIELD: chemistry.
SUBSTANCE: invention discloses a compound of formula I
, in which radicals and groups are described in the claims. Said compounds are 5-hydroxytryptamine-6 (5-HT6) ligands and can be used to treat central nervous system disorders associated with or influenced by the 5-HT6 receptor. The invention also relates to a pharmaceutical composition and a method of treating said disorders.
EFFECT: high efficiency of using said derivatives.
19 cl, 13 tbl, 204 ex
| Title | Year | Author | Number |
|---|---|---|---|
| AMINOTETRALINE DERIVATIVES CONTAINING THEIR PHARMACEUTICAL COMPOSITIONS AND USING THEM IN THERAPY | 2010 |
|
RU2546649C2 |
| NEW COMPOUNDS AND COMPOSITIONS FOR NAMPT INHIBITION | 2011 |
|
RU2617988C2 |
| PHOSPHOINOSITIDE-3-KINASE INHIBITORS AND PHARMACEUTICAL COMPOSITIONS CONTAINING SAID INHIBITORS | 2007 |
|
RU2437888C2 |
| APOPTOSIS INDUCING AGENTS SELECTIVE FOR Bcl-2 FOR CANCER AND IMMUNE DISEASES TREATMENT | 2013 |
|
RU2621052C2 |
| BCL-2-SELECTIVE APOPTOSIS-INDUCING AGENTS FOR TREATING CANER AND IMMUNE DISEASES | 2010 |
|
RU2542994C2 |
| SIGMA-LIGANDS FOR APPLICATION IN PREVENTION AND/OR TREATMENT OF POSTOPERATIVE PAIN | 2011 |
|
RU2569055C2 |
| PHARMACEUTICAL COMPOSITION, INCLUDING TRICYCLIC SULFUR-CONTAINING 1,2-DIHYDROQUINOLINE DERIVATIVE FOR INHIBITION OF REPLICATION OF BETA CORONAVIRUSES, INCLUDING SARS-CoV-2, AND METHOD OF ITS USE | 2021 |
|
RU2814434C1 |
| SUBSTITUTED SULPHONAMIDE DERIVATIVES | 2009 |
|
RU2503674C2 |
| BLC-2 SELECTIVE AGENTS CAUSING APOPTOSIS FOR TREATING CANCER AND IMMUNE DISEASES | 2009 |
|
RU2497822C2 |
| DERIVATIVES OF NITROGEN-CONTAINING HETEROCYCLIC COMPOUNDS, METHODS FOR THEIR PREPARING, PHARMACEUTICAL COMPOSITION BASED ON THEREOF AND METHODS FOR TREATMENT OF INFLAMMATORY DISEASES AND RESPIRATORY WAYS DISEASES | 2001 |
|
RU2265011C2 |
